Iwasaki Y, Ikeda K
Fourth Department of Internal Medicine, Toho University.
Rinsho Shinkeigaku. 1999 Dec;39(12):1253-5.
In the treatment of cancers and infectious diseases, several drugs are administered simultaneously. Riluzole is a only drug which prolongs survival in amyotrophic lateral sclerosis (ALS) patients, however its effect is modest. We review the preclinical data supporting combination treatment for ALS and discuss the possible combination treatment in patients with ALS. In vitro studies showed favorable results in combination of neurotrophic factors. The combination of BDNF and GDNF reduced motor neuron death after axotomy for more than either factor alone. CNTF and BDNF combination treatment in wobbler mice arrested paw deformity. In the treatment of ALS, riluzole is the only drug available by prescription. When combination treatment is considered in ALS, the most effective combination need to be addressed.
在癌症和传染病的治疗中，几种药物会同时给药。利鲁唑是唯一一种能延长肌萎缩侧索硬化症（ALS）患者生存期的药物，但其效果并不显著。我们回顾了支持ALS联合治疗的临床前数据，并讨论了ALS患者可能的联合治疗方案。体外研究表明神经营养因子联合使用效果良好。BDNF和GDNF联合使用在轴突切断后减少运动神经元死亡的效果比单独使用任何一种因子都要好。CNTF和BDNF联合治疗摇摆小鼠可阻止爪畸形。在ALS的治疗中，利鲁唑是唯一可凭处方获得的药物。当考虑ALS的联合治疗时，需要确定最有效的联合方案。
